Your browser doesn't support javascript.
loading
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials.
Gane, Edward; de Ledinghen, Victor; Dylla, Douglas E; Rizzardini, Giuliano; Shiffman, Mitchell L; Barclay, Stephen T; Calleja, Jose Luis; Xue, Zhenyi; Burroughs, Margaret; Gutierrez, Julio A.
  • Gane E; Faculty of Medicine, University of Auckland, Auckland, New Zealand.
  • de Ledinghen V; Centre d'Investigation de la Fibrose Hépatique, Bordeaux University Hospital, Pessac, France.
  • Dylla DE; INSERM U1053, Bordeaux University, Bordeaux, France.
  • Rizzardini G; AbbVie Inc, North Chicago, Illinois, USA.
  • Shiffman ML; 1st Division of Infectious Diseases, ASST Fatebenefratelli-Sacco, Milan, Italy.
  • Barclay ST; Liver Institute of Virginia, Bon Secours Mercy Health, Richmond, Virginia, USA.
  • Calleja JL; Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK.
  • Xue Z; Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Burroughs M; AbbVie Inc, North Chicago, Illinois, USA.
  • Gutierrez JA; AbbVie Inc, North Chicago, Illinois, USA.
J Viral Hepat ; 28(11): 1635-1642, 2021 11.
Article en En | MEDLINE | ID: mdl-34448313
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antivirales / Hepatitis C Crónica Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article